Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UC Davis MIND Institute, Sacramento, CAAttention Deficit Hyperactivity Disorder (ADHD)+3 MoreMethylphenidate Oral Solution - Drug
Eligibility
6 - 17
All Sexes
What conditions do you have?
Select

Study Summary

This trialstudies the effects of medication on cognition in kids & teens with intellectual disability and ADHD. 68 participants will receive drug or placebo in a 1:1 ratio, monitored and assessed for 5 weeks.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Fragile X Syndrome
  • Intellectual Disability
  • Down Syndrome

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 11 weeks

11 weeks
Composite score of NIHTB-CB Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests.
Conners 3 ADHD Rating Scale Hyperactivity/Impulsivity Scale
Conners 3 ADHD Rating Scale Inattention Scale

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Methylphenidate
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

68 Total Participants · 2 Treatment Groups

Primary Treatment: Methylphenidate · Has Placebo Group · Phase 1

Placebo
Drug
PlaceboComparator Group · 1 Intervention: Methylphenidate Oral Solution · Intervention Types: Drug
Methylphenidate
Drug
ActiveComparator Group · 1 Intervention: Methylphenidate Oral Solution · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 11 weeks

Who is running the clinical trial?

University of California, DavisLead Sponsor
853 Previous Clinical Trials
5,017,635 Total Patients Enrolled
7 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
266 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

Age 6 - 17 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your IQ score falls between 50 and 80.
You have a mental age of at least 4 years.
You have an intellectual disability.
You have been diagnosed with ADHD.

Frequently Asked Questions

How many participants are eligible for this clinical trial?

"Yes, the research hosted on clinicaltrials.gov reveals that this medical experiment is currently searching for participants. This investigation was first posted in February of 2023 and has been recently updated as October 24th 2022. There are 68 slots available across 3 different sites." - Anonymous Online Contributor

Unverified Answer

Are recruitment efforts for this experiment still ongoing?

"The details on clinicaltrials.gov indicate that this trial is still open for enrolment, with the initial posting occurring February 1st 2023 and the most recent update issued October 24th 2022." - Anonymous Online Contributor

Unverified Answer

What potential risks accompany taking Methylphenidate?

"The safety of Methylphenidate is judged to be a 1 due to its Phase 1 status, indicating that there have been few studies conducted on the medication's efficacy and safety." - Anonymous Online Contributor

Unverified Answer

Is there an age restriction to qualify for this clinical investigation?

"This trial is seeking participants who are within the juvenile age range, being over 6 and under 17 years of age." - Anonymous Online Contributor

Unverified Answer

Who has the capacity to be included in this experiment?

"This medical trial is currently enrolling 68 minors (age 6-17) with intellectual disability and ADHD. All participants must be capable of valid NIHTB-CB tests, have an IQ between 50-80, a mental age score of 4 or above on the Stanford Binet test, and provide diagnosis for both conditions." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.